Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout

Roberto E. Favoni, Angela Alama

Research output: Contribution to journalArticle

Abstract

Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.

Original languageEnglish
Pages (from-to)11-24
Number of pages14
JournalDrug Discovery Today
Volume18
Issue number1-2
DOIs
Publication statusPublished - Jan 2013

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout'. Together they form a unique fingerprint.

  • Cite this